Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2009-08-11
2011-11-01
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S138100, C424S141100, C424S143100, C530S387100, C530S387300, C530S388100, C530S388220
Reexamination Certificate
active
08048415
ABSTRACT:
Compounds, compositions and methods for promoting or inhibiting angiogenesis, and screening methods for identifying compounds are disclosed. The compounds bind to F1 ATP synthase, particularly to the alpha and/or beta subunits of F1 ATP synthase. When bound to these subunits, they can function as angiostatin agonists, antagonists, partial agonists, inverse agonists, or allosteric modulators. When the compounds mimic or enhance the activity of angiostatin, they inhibit angiogenesis. When the compounds inhibit the ability of angiostatin to bind F1 ATP synthase and are either inactive at inhibiting angiogenesis or directly promote angiogenesis, or if they inhibit the activity of angiostatin, they promote angiogenesis. The compounds can be, for example, antibodies, antibody fragments, enzymes, peptides, nucleic acids such as oligonucleotides, or small molecules. The antibodies can be monoclonal, humanized, or polyclonal antibodies. The compounds can be conjugated to or combined with various cytotoxic agents and/or labeled compounds. Methods for promoting angiogenesis can be used to introduce vasculature to areas in a patient that can benefit from such increased vasculature. Methods for inhibiting angiogenesis can be used to treat disorders mediated by angiogenesis, for example, tumors, autoimmune disorders such as rheumatoid arthritis, and the like.
REFERENCES:
patent: 5086164 (1992-02-01), Maione et al.
patent: 5112946 (1992-05-01), Maione
patent: 5284827 (1994-02-01), Maione et al.
patent: 5512591 (1996-04-01), Halperin et al.
patent: 5593664 (1997-01-01), Wright et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5681372 (1997-10-01), Magits
patent: 5744492 (1998-04-01), Kohn et al.
patent: 5786150 (1998-07-01), Hillman et al.
patent: 5837682 (1998-11-01), Folkman et al.
patent: 5945403 (1999-08-01), Folkman et al.
patent: 6024688 (2000-02-01), Folkman et al.
patent: 6025353 (2000-02-01), Masferrer
patent: 6056973 (2000-05-01), Allen et al.
patent: 6110722 (2000-08-01), Hillman et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6201104 (2001-03-01), MacDonald
patent: 6380253 (2002-04-01), Das
patent: 6387371 (2002-05-01), Hudziak et al.
patent: 6572856 (2003-06-01), Taylor et al.
patent: 7595047 (2009-09-01), Moser et al.
patent: WO 99/59620 (1999-11-01), None
patent: WO 99/66038 (1999-12-01), None
patent: WO 00/32631 (2000-06-01), None
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction, pp. 491-495, 1994.
Chica et al, Curr Opin Biotechnol 16(4):378-84, Aug. 2005.
Witkowski et al, Biochemistry 38(36): 11643-50, Sep. 7, 1999.
Seffernick et al, J Bacteriol 183 (8): 2405-10, Apr. 2001.
Stancoviski et al, PNAS; 88: 8691-8695, 1991.
Jiang et al, J. Biol. Chem. 280 (6): 4656-4662, Feb. 11, 2005.
Freshney Ri et al. Culture of Animal Cells, A Manual of Basic Technique. Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer GB. Another anniversary for the war on cancer. Bio/Technology. Mar. 1994. 12: 320.
Gura T. Systems for identifying new drugs are often faulty. Science. Nov. 7, 1997; 278: 1041-1042.
Jain RK. Barriers to drug delivery in solid tumors. Scientific American. Jul. 1994; 271(1): 58-65.
Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science. Jun. 21, 1991; 252: 1657-1662.
Harris WJ and Emery S. Therapeutic antibodies—the coming of age. TIBTECH. Feb. 1993; 11: 42-44.
Amalfitano A and Parks RJ. Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy. Current Gene Therapy. 2002; 2: 111-133.
Verma IM and Somia N. Gene therapy—promises, problems and prospects. Nature. Sep. 18, 1997; 389: 239-242.
The Department of Health and Human Services has released a memorandum dated Jan. 14, 2003. p. 1-3.
Pandha HS et al. Oncological applications of gene therapy. Current Opinions in Investigational Drugs. 2000; 1(1): 122-134.
Almus FE et al. Mechanism for diminished tissue factor expression by endothelial cells cultured with heparin binding growth factor-1 and heparin. Blood. Mar. 15, 1991; 77(6): 1256-1262.
Langer DJ et al. Regulation of the endothelial cell urokinase-type plasminogen activator receptor. Evidence for cyclic AMP-dependent and protein kinase C-dependent pathways. Circulation Research. Feb. 1993; 72(2): 330-340.
Kohn EC et al. Angiogenesis: role of calcium-mediated signal transduction. Proc. Natl. Acad. Sci. USA. Cell Biology. Feb. 1995. 92: 1307-1311.
Morisaki N. et al. Mechanism of angiogenic effects of saponin from GinsengRadix rubrain human umbilical vein endothelial cells. British Journal of Pharmacology. 1995; 115: 1188-1193.
Griffioen AW et al. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood. Jul. 15, 1996; 88(2): 667-673.
Malinda KM et al. Thymosin β4stimulates directional migration of human umbilical vein endothelial cells. FASEB J. May 1997; 11: 474-481.
Papapetropoulos A et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. Dec. 1997; 100(12): 3131-3139.
Wang J et al. Effect of a novel inhibitory mAb against β-subunit of F1F0 ATPase on HCC. Cancer Biology & Therapy. Nov. 2008; 7(11): 1829-1835.
Genentech Inc., “Highlights of Prescribing Information, Herceptin,” (2008).
Moser, et al., “Endothelial Cell Surface F1F0 ATP Synthesis and is Inhibited by Angiostatin,”Proc. Natl. Acad. Sci. 98(12):6656-61 (2001).
Moser, et al., “Angiostatin Binds ATP Synthase on the Surface of Human Endothelial Cells,” Proc. Natl. Acad. Sci. 96(12):2811-16 (1999).
Boyer, “The ATP Synthase—A Splendid Molecular Machine,”Annnu. Rev. Biochem. 66:717-749 (1997).
Das, et al., “A Novel Ligand in Lymphocyte-mediated Cytotoxicity: Expression of the β Subunit of H+Transporting ATP Synthase on the Surface of Tumor Cells Lines,”J. Exp. Med. 180:273-281 (1994).
Dunn, et al., “Monoclonal Antibodies toEscherichia coliF1-ATPase,”J. Biol. Chem. 260:10418-10425 (1985).
Elston, et al., “Energy transduction ATP Synthase,” Nature 39:510-513 (1998).
Feller, et al., “A monoclonal antibody detecting dipeptideylpeptidase IV in human tissue,”Virchos Arch. A. Pathol. Anata. Histopathol. 409(2):263-273 (1986).
Gogol, et al., “Cryoelectron icroscopy ofescherichia coliF1Adenosinetriphosphatase Decorated with monoclonal Antibodies to Individual Subunits of the Complex,”Biochem. 28:4717-4724 (1989).
Hartel, et al., “Characterization of Different Forms of Dipeptidyl Peptidase IV from Rat Liver and Hepatoma by Monoclonal Antibodies,”Adv. Exp. Med. Biol. 240:206-214 (1988).
Kataoka, et al., “Nucleotide sequence of a cDNA for the α subunit of human mitochondrial ATP Synthase,”Biochimica et Biophysica Acta1089:393-395 (1991).
Miles, et al., “Roley of Cell-Surface Lysines in Plasminogen Binding to Cells: Identification of α-Enolase as a Candidate Plasminogen Recepor,”Biochemistry30(6):1682-1691 (1991).
Moradi-Ameli, et al., “Chacterization of monoclonalantibodies against mitachondrial F1-ATPase,”PNAS80:6167-6171 (1983).
Moreno, et al., “Vascular-type H+-ATPase regi;ates cytoplasmic pH in Toxoplasma gondii tachyzoites,”Biochem. J. 330:853-860 (1998).
Nelson, et al., “Immunochemical Analysis of the membrane Proteins of Rat Liver and Zajdela Hepatoma Mitochondria,”Arch. Biochem. Biophys. 234:24-30 (1984).
Rao, et al., “The Defective Proton—ATPase ofuncAMutants ofEscherichia coli: ATP-Binding an ATP-Induced Conformational Change in Mutant α-Subunits”,Archives of Biochemistry and Biophysics255(2):309-315 (1987).
Moser Tammy L.
Pizzo Salvatore V.
Stack Mary S.
Duke University
Huynh Phuong
Myers Bigel Sibley & Sajovec P.A.
Northwestern University
LandOfFree
Compositions and methods for promoting or inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for promoting or inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for promoting or inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295970